CAMP4 Therapeutics said late Thursday it priced its initial public offering of about 6.8 million common shares at $11 per share for expected gross proceeds of about $75 million.
Underwriters have been granted a 30-day option to buy up to about 1 million additional shares.
Shares of the biotechnology company are expected to begin trading on Nasdaq this Friday, under the ticker symbol, "CAMP." The IPO is set to close Oct. 15.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.